+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 40Years - 80Years
All Genders
ID07725939

Evaluating the Effectiveness and Safety of Galvokimig Injection in Adults with Moderate-to-Severe COPD and Chronic Bronchitis Over 24 to 52 Weeks

Led by UCB Biopharma SRL · Updated on 2026-10-27

402

Participants Needed

23

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug Galvokimig compared to a placebo to see how it affects the time until the first acute worsening exacerbation of chronic obstructive pulmonary disease COPD in people with moderate-to-severe COPD who also have chronic bronchitis. This Phase 2 study focuses on participants aged 40 to 80 with a history of COPD exacerbations and chronic bronchitis symptoms. Participants are randomly assigned to receive one of two predefined doses of Galvokimig or a matching placebo. The study treatment is given as a solution for injection over a period ranging from 24 to 52 weeks. The purpose is to assess the drugs effect on reducing the frequency and timing of COPD exacerbations during this treatment phase. During the study, participants will be monitored regularly to measure lung function, quality of life related to respiratory health, and the number and severity of COPD exacerbations. Safety is closely followed by tracking adverse events up to 60 weeks. The main outcome is the time until the first moderate or severe COPD exacerbation, with additional assessments including lung function tests and patient questionnaires. Total study participation may last up to about 60 weeks.

CONDITIONS

Brief Title

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Research Team

U

UCB Cares

U

UCB Care

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here